Literature DB >> 6641647

Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children.

J W Paxton, M G Aman, J S Werry.   

Abstract

Hourly salivary concentrations of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (EP) were studied during 2 consecutive days in a group of epileptic children receiving twice daily CBZ monotherapy either as the tablet or syrup formulation. Relatively large fluctuations were observed for both CBZ (mean, 57%; range, 32-100%) and EP (mean, 97%; range, 19-189%) during a dosage interval. However, concentrations of EP were generally much lower, approximately 34% of corresponding CBZ levels, and in absolute terms the concentration-time curves for EP appeared much less variable. Further evidence supporting extensive CBZ concentration fluctuations during the day was provided by an additional group of 30 epileptic children receiving CBZ monotherapy whose time of dosage was manipulated to achieve peak and trough concentrations during assessment with a psychomotor test battery. Changes in salivary CBZ concentrations within subjects ranged from 4 to 272% (median, 65%), excluding two atypical cases who showed greater than 10-fold increases in the expected high concentration. These results suggest that in children there is a substantial risk of error in the interpretation of CBZ concentrations from a single sample without consideration of the time of last dose. The implications of these findings for clinical treatment with regard to the appearance of side effects and changes in psychomotor function are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641647     DOI: 10.1111/j.1528-1157.1983.tb04634.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

Review 1.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

3.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

5.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.